Drug intelligence / Profile preview

FL763

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules

Overview

FL763 is a small molecule camptothecin analog currently in preclinical development by Canget BioTekpharma. It is designed as a derivative of FL118, a potent anti-tumor agent known for its ability to selectively inhibit the expression of multiple anti-apoptotic proteins, including Survivin (BIRC5), Mcl-1, XIAP, and c-IAP2. By downregulating these key survival factors, FL763 aims to overcome drug resistance and induce apoptosis in cancer cells. The compound has demonstrated activity in in vivo models, with a primary focus on the treatment of ovarian cancer.

Targets

MCL1 (Myeloid cell leukemia sequence 1)XIAPBIRC5 (Survivin)

Beyond the preview

Go deeper on FL763.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL763.

Explore the full profile